Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub‐Saharan Africa: Rationale and Design of the REACH Trial

BACKGROUND: Sickle cell anemia (SCA) is an inherited hematological disorder that causes a large but neglected global health burden, particularly in Africa. Hydroxyurea represents the only available disease‐modifying therapy for SCA, and has proven safety and efficacy in high‐resource countries. In s...

Descripción completa

Detalles Bibliográficos
Autores principales: McGann, Patrick T., Tshilolo, Léon, Santos, Brigida, Tomlinson, George A., Stuber, Susan, Latham, Teresa, Aygun, Banu, Obaro, Stephen K., Olupot‐Olupot, Peter, Williams, Thomas N., Odame, Isaac, Ware, Russell E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825070/
https://www.ncbi.nlm.nih.gov/pubmed/26275071
http://dx.doi.org/10.1002/pbc.25705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825070/
https://www.ncbi.nlm.nih.gov/pubmed/26275071
http://dx.doi.org/10.1002/pbc.25705

Ejemplares similares